Background
Ocular melanoma is a rare, generally lethal, malignancy that can arise in the uveal tract, the conjunctiva, or the ocular adnexa (eyelid or orbit). Orbital melanoma occurs either as primary disease, as secondary disease (local invasion from an ocular or sinonasal primary tumour), or as a metastasis from the contralateral eye or from the skin. Melanoma accounts for 5–20% of metastatic and secondary orbital malignancies, but only a very small proportion of primary orbital neoplasia [
1‐
3]. Primary orbital melanoma (POM) is extremely rare, with approximately 60 cases reported to date. It is possible that POM arise from melanocytic cells lining the leptomeninges or ciliary nerves, or from ectopic intraorbital nests of melanocytes [
4]. POM can occur de novo, but it is sometimes reported in association with pigmentary changes of the periocular tissues – such as naevus of Ota, blue cellular naevus or oculo-dermal melanosis [
5]. The prognosis of POM appears to be quite variable. Generally, the disease is considered to have a very poor prognosis, but there appears to be a subset of patients who have long-survival [
6,
7].
The genetic aberrations that drive cutaneous melanoma (CM) and uveal melanoma (UM) are well-described and quite distinct from each other. Mutations in the RAS pathway are found in > 75% of CM and have also been described in conjunctival melanoma, whereas mutations in
GNAQ and
GNA11 are found in ~ 85% of UM [
8,
9]. Several genes have also recently been implicated in UM prognosis, such as
BAP1,
SF3B1 and
EIF1AX. There are no data, however, describing the genetic alterations found in POM. In this study, we examined POM for alterations in candidate melanoma driver genes (
BRAF, NRAS, KRAS, GNA11, GNAQ) and genes implicated in UM prognosis (
EIF1AX, SF3B1, BAP1).
Discussion
In this study we examined the largest reported clinical series of POM for mutations implicated in melanoma, giving the first report of genetic alterations in this rare tumour. It was demonstrated that POM appears to be genetically distinct to CM, but shares some overlapping features with UM; however, a distinct driver mutation might exist in at least some cases of POM. Furthermore, mutations in
SF3B1 and
EIF1AX might influence prognosis. POM is an extremely rare tumour, with approximately 60 cases reported to-date in the literature. One striking feature is the highly variable prognosis – whilst most reported cases have a dismal prognosis, a subset of patients appear to follow a relatively benign course [
6,
7]. This feature was certainly observed in the patient cohort used in this study – some patients had aggressive primary disease with widespread systemic involvement and rapid deterioration; whereas other patients survived for more than a decade [
7].
POM were not associated with monosomy 3 in the small number of tested samples, which is a frequent chromosomal alteration in UM associated with poor prognosis [
14]. In addition, although polysomy 8q was observed in 4/7 POM in this cohort, all were associated with patients who had a good prognosis, which again is contrary to its association with a poor outcome in UM. These data would suggest that chromosomal alterations in POM do not follow a similar pattern to that observed in UM, although testing of more cases will be important. Similarly, loss of nBAP1, which is associated with a poor prognosis and monosomy of chromosome 3 in UM [
12,
15,
16] was noted in only two cases and was neither associated with a poor outcome nor with monosomy of chromosome 3.
Mutations in genes of the
MAPK pathway are known to drive the majority of cases of CM. Mutations in
BRAF account for the majority of driver mutations (up to 60%) [
17]. However, mutations in
NRAS and
KRAS are also relatively frequent (13–25 and 2%, respectively) [
18]. Screening for mutations in these genes did not, however, reveal any changes in our POM cohort. Mutations in two Gq alpha sub-unit genes, which interact indirectly with the MAPK pathway, are found frequently in UM:
GNAQ (~ 45%) and
GNA11 (~ 35%) [
19,
20]. In our cohort, two cases (patients 4 and 5) were found to carry a heterozygous mutation in
GNAQ (p.Q209L). This change is the most frequently observed change in
GNAQ mutant UM, occurring in one third of such cases [
21]. This dominant-negative mutation alters the catalytic (GTPase) domain of GNAQ and results in a constitutively active protein [
22]. Expression of
GNAQ p.Q209L in mice resulted in malignant transformation of melanocytes and increased signalling through the MAPK pathway [
21]. It is often speculated whether POM cases are true primary disease, or whether an occult uveal source might be present. It was considered necessary, therefore, to assess whether these two cases could be occult uveal tumours, given the frequency of
GNAQ p.Q209L in UM. The imaging of both cases was reviewed, and a uveal source could not be discerned. The tumour histology of the cases was re-reviewed by an expert pathologist, without knowledge of the genetic findings. In one case harbouring the
GNAQ change, there was evidence of very minor choroidal pigmentary changes which could represent a possible uveal source; in the other case, there was insufficient biopsy material to fully exclude a uveal source. It is possible, therefore, that these two cases might indeed have an occult uveal source. It is also plausible, however, that these are POM that share common genetic features with UM. Mutations in other G protein genes, such as
CYSLTR2 and
PLCB4 have been reported in a small number of UM patients and these could be sequenced in our cohort to extend the study further [
23,
24].
Next, it was considered whether mutations in SF3B1 or EIF1AX contributed to the pathogenesis of disease and/or variable prognosis seen within our cohort. Mutually exclusive changes in both genes were found (which might associate with good prognosis), highlighting another feature that overlaps with the genetic landscape of UM. Sequencing of exon 14 of SF3B1 revealed a recurrent heterozygous mutation (c.G1874A, p.R625H) in four patients – cases 4, 9, 11 and 12. It was noted that all four of these patients had a favourable outcome, with a mean survival to-date of 104.8 months (22–188 months). Three of these patients have not had any local or systemic progression or recurrence of disease. One patient – case 9 – harbouring the SF3B1 mutation had systemic progression and has since died, however, this was after a remarkable disease-free period of 13 years. The presence of the SF3B1 mutation was confirmed in both the primary and recurrent tumour of this individual. In contrast, no patients with poor survival, or early local/systemic progression, carried the SF3B1 change. This would suggest that the observed mutation in SF3B1 confers a favourable prognosis in POM.
SF3B1 encodes splicing factor 3b, subunit 1 protein, which is a component of the splicing factor 3b protein complex. This complex is part of the spliceosome, the macromolecular structure responsible for transcriptional mRNA processing. Mutations in
SF3B1 have been implicated as a common driver mutation in myelodysplatic syndromes (MDS), myelofibrosis and chronic myeloid leukaemia [
25,
26]. In MDS,
SF3B1 mutations have been associated with favourable overall survival and a lower likelihood of transformation into acute leukaemia [
27,
28]. More recently, mutations in
SF3B1 (particularly at codon 625) have been identified in various pigmented tumours, including UM [
29], mucosal melanoma [
30], leptomeningeal melanoma [
31] and blue naevi-like cutaneous melanoma [
32]. They are, however, rare in CM [
33,
34]. As with MDS,
SF3B1 mutations confer a favourable prognosis in UM, with lower age of onset and concurrent disomy 3 [
35]. However, it should be noted that
SF3B1 mutant UM are reported to give rise to late metastasis (median 8.2 years after initial diagnosis) [
36]. Furthermore, The Cancer Genome Atlas project reported that UM cases with
SF3B1 mutations have an intermediate prognosis [
9]. One of our patients harbouring the change (case 9) did indeed have late onset metastasis to the brain (13 years after diagnosis). It is also interesting to note that secondary melanoma within the orbit was noted to have frequent late recurrence, and the incidence of
SF3B1 in these tumours could be studied [
37].
One patient, case 10, was found to harbour a heterozygous mutation in exon 1 of
EIF1AX (c.A11T, p.N4S). This patient also had a highly favourable prognosis.
EIF1AX, located on the X chromosome, encodes the eukaryotic translation initiation factor 1A protein. This factor is essential in the initiation phase of translation, through interaction with tRNA and the ribosome [
38]. Mutations in exon 1 or 2 of this gene have been frequently reported in UM [
39], but also rarer melanoma types including blue-nevus associated melanoma and leptomeningeal melanoma [
33,
34].
EIF1AX mutations are associated with good prognosis disomy 3 UM, and usually occur in non-metastatic cases [
39‐
41]. This is in agreement with the patient reported here, who displayed all of these features to-date with follow up of over 2 years. It is highly plausible, therefore, that mutations in
EIF1AX also correspond to good prognosis in POM.
It must be considered whether the changes seen in
SF3B1 and
EIF1AX are the driver mutation of POM, or a secondary change in the tumour. It is thought that mutations in
SF3B1 arise as a second genetic change in UM and blue nevus-like melanoma, after initial mutation in
GNAQ or
GNA11; however,
SF3B1 changes can be driver mutations in MDS [
25,
34]. Indeed, in UM, mutations in either gene (
SF3B1 or
EIF1AX) are almost never seen in the absence of a
GNAQ or
GNA11 mutation [
13]. Whole exome or whole genome sequencing of these tumours will be necessary to elucidate the full spectrum of genetic mutations in POM. A further consideration is the role of underlying precursor or premalignant lesions in the genetic aetiology of POM. The tumour can arise following malignant transformation of pigmentary changes of the periocular tissues – such as naevus of Ota, blue cellular naevus or oculo-dermal melanosis [
5]. This was the case in three individuals studied here (Cases 6, 8 and 9; in addition, minor increased choroidal pigmentation was observed on re-examination of Case 4. It would be interesting to study the genetic aberrations in the premalignant tissue, as this might shed light on the temporal occurrence of sequential mutations and their role in pathogenesis.